Midazolam inhibits the proliferation of human head and neck squamous carcinoma cells by downregulating p300 expression.
The objective of this study was to investigate the mechanism of midazolam in inhibiting the proliferation of hypopharyngeal squamous carcinoma cells. Cultured FaDu cancer cells were treated with different concentrations of midazolam. MTT and BrdU incorporation assays were then used to evaluate cancer cell proliferation. The mRNA and protein levels of p300, a key factor involved in the tumorigenesis of numerous cancers, were measured with RT-PCR and Western blotting, respectively. Midazolam inhibited the expression of p300 and the proliferation of FaDu cells. Additionally, knockdown of p300 resulted in increased expression of p21 and p27 and decreased expression of p-Rb while inhibiting the proliferation of FaDu cells. Midazolam inhibits the proliferation of human head and neck squamous carcinoma cells by downregulating p300. Midazolam may be useful for the treatment of hypopharyngeal squamous cancers.
Department of Anesthesiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, China, yunlingdousci@163.com.
Yun-Ling
YL
Dou
Jia-Ping
JP
Lin
Feng-En
FE
Liu
Ling-Yan
LY
Wang
Hai-Hua
HH
Shu
Nan
N
Jiang
Yan
Y
Xie
Qin
Q
Duan
D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology; D049109:Cell Proliferation / Q000187:drug effects*; D015536:Down-Regulation; D050881:E1A-Associated p300 Protein / Q000037:antagonists & inhibitors / Q000502:physiology*; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007012:Hypopharyngeal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008874:Midazolam / Q000494:pharmacology*; D016160:Retinoblastoma Protein / Q000502:physiology; D000077195:Squamous Cell Carcinoma of Head and Neck; D014407:Tumor Cells, Cultured
D016160:Retinoblastoma Protein; D050881:E1A-Associated p300 Protein; C494360:EP300 protein, human; D008874:Midazolam